1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)

Ravi A. Madan, James L. Gulley, Y-T. Tsai et al.|Annals of Oncology|2022

Cited by 2